CliffBio
small molecule

VYNDAQEL

TAFAMIDIS MEGLUMINE

Loss of exclusivityDecember 2026latest FDA-listed patent expiry
CompanyFOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC

Drug detail

Brand nameVYNDAQEL
Active ingredientTAFAMIDIS MEGLUMINE
Strength20MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
7214696December 2026use U-2524
7214695December 2026substance, product

Regulatory exclusivity

CodeExpires
ODE-237May 2026

More from FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VYNDAQEL patent cliff — loss of exclusivity December 2026 | CliffBio